Skip to main content

Dercum's Disease

2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Caliway Biopharmaceuticals
Caliway BiopharmaceuticalsTaiwan - New Taipei City
2 programs
2
10 mg CBL-514 per injectionPhase 21 trial
CBL-514 injectionPhase 21 trial
Active Trials
NCT05387733Completed12Est. Apr 2023
NCT06303570Active Not Recruiting19Est. Apr 2026

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
Caliway BiopharmaceuticalsCBL-514 injection
Caliway Biopharmaceuticals10 mg CBL-514 per injection

Clinical Trials (2)

Total enrollment: 31 patients across 2 trials

A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease Lipomas

Start: Nov 2024Est. completion: Apr 202619 patients
Phase 2Active Not Recruiting
NCT05387733Caliway Biopharmaceuticals10 mg CBL-514 per injection

A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With Dercum's Disease Lipomas

Start: Oct 2022Est. completion: Apr 202312 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.